Home >> ATI-2341
Related Products
ATI-2341 CXCR4 allosteric agonist

Catalog No.B7814
Size Price Stock
1mg
$124.00
Please Inquire
5mg
$418.00
Please Inquire

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

ATI-2341

ATI-2341 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ATI-2341 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1337878-62-2 SDF Download SDF
Synonyms N/A
Chemical Name (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S)-11-(4-aminobutyl)-14-((Z)-((2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S,21Z,23S,24Z,26S,27Z,30Z,32S,33Z)-17,20-bis(4-aminobutyl)-11-(3-guanidinopropyl)-1,4,7,10,13,16,19,22,25,28,31,34-dodecahydroxy-23-(3-hydroxy-3-iminop
Canonical SMILES CCCCCCCCCCCCCCC/C(O)=N/[[email protected]@](/C(O)=N/C/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](C(O)=O)([H])CC(C)C)([
Formula C104H178N26O25S2 M.Wt 2256.82
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

IC50: 194 nM

ATI-2341 is a CXCR4 allosteric agonist.

Chemokine CXC-type receptor 4 (CXCR4) and its ligand CXCL12 mediate the retention of polymorphonuclear neutrophils and hematopoietic stem and progenitor cells in the bone marrow. Drugs disrupting CXCL12-mediated chemoattraction of CXCR4-expressing cells are useful for hematopoietic stem and progenitor cells (HSPCs) collection.

In vitro: ATI-2341 could inhibit NKH477-induced cAMP accumulation in CXCR4-HEK cells dose-dependently, but showed no effect in naive HEK-293 parental cells. Pretreatment of CXCR4- HEK cells with pertussis toxin completely abrogated the ability of ATI-2341 to inhibit cAMP accumulation. ATI-2341 could also induce a dose-dependent increase in intracellular calcium in cells transfected with wild-type CXCR4 whereas having no effect on untransfected cells. Activation of such signaling pathway by ATI-2341 was dependent on a fully functional CXCR4 receptor since ATI-2341 was not able to mobilize calcium in cells transfected with a CXCR4 receptor variant [1].

In vivo: ATI-2341 could induce dose-dependent peritoneal recruitment of polymorphonuclear neutrophils (PMNs) when i.p. administered to mice. However, when systemically administered by i.v. bolus, ATI-2341 acted as an antagonist and could dose-dependently mediate release of PMNs from the bone marrow of mice and cynomolgus monkeys. In addition, ATI-2341-mediated release of granulocyte/macrophage progenitor cells from the bone marrow was further confirmed by colony-forming assays [1].

Clinical trial: Up to now, ATI-2341 is still in the preclinical development stage.

Reference:
[1] Tchernychev B et al.  Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc Natl Acad Sci U S A.2010 Dec 21;107(51):22255-9.